Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Isa-VCd induction in NDMM patients with severe renal impairment show no new...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

ATRA-ATO regimen with idarubicin could become the new standard of care in high...

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Ibrutinib and venetoclax continue to provide benefits for patients with chronic...

Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL ( Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy )

Lower levels of inflammatory markers and tumour burden is linked to...

Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma ( Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France )

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL...

Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation ( Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy )

More from ecancer